The Drug-Induced Respiratory Disease Website and App

Anticoagulants, direct oral (anti-thrombin, -IIa, -Xa) - NOAC

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.a

Pneumonitis (interstitial lung disease/ILD)

First cases observed in Japan

Publications

Capron T, Botto G, Roujon JJ, Miltgen J, Berard H

Drug-induced interstitial lung disease: Indictment for apixaban.

Respiratory medicine and research 2023 May 19;84;101024 — 2023 May 19 — 101024

Chan YH, Chao TF, Chen SW, Lee HF, Chen WM, Li PR, Yeh YH, Kuo CT, See LC, Lip GYH

Development of Interstitial Lung Disease Among Patients With Atrial Fibrillation Receiving Oral Anticoagulants in Taiwan.

JAMA network open 2022 Nov 01;5;e2243307 — 2022 Nov 01 — e2243307

Tomari S, Homma K, Noguchi T, Aiba T, Matsuki T, Suzuki R, Koga M, Takigami M, Tagawa H, Hashimoto T, Toyoda K

Development of Interstitial Lung Disease after Initiation of Apixaban Anticoagulation Therapy.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 2016 Jul;25;1767-1769 — 2016 Jul — 1767-1769